Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions highlight the clinical significance of andexanet alfa, with posts mentioning the rapid thrombin generation restoration within minutes, and comparing its effects to other agents like 4F-PCC. The tone is informative and evaluative, emphasizing the importance of the findings for medical practice.
Most posts acknowledge the positive effects of andexanet alfa, supporting its efficacy and safety based on the studies discussed.
Discussions focus on clinical trial results, safety profiles, and comparisons with other reversal agents, indicating a strong interest in the topic.
Posts reference specific studies, mechanisms, and clinical implications, showing moderate to deep engagement with the research details.
Posts imply that the publication could influence clinical practices and guidelines, pointing to notable potential impact in medical treatment.
#chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRXTVuT Reversal agents for DOACs: ANNEXA https://t.co/Czb2dMISBX Praxbind https://t.co/cAtqnc3FWD
In the ANNEXA-A and -R studies, andexanet alfa (AA) reduced anti-FXa activity and restored thrombin generation in healthy older volunteers Maximal effect was noted within 2-5 min of bolus and sustained throughout the infusion https://t.co/DzXjwZhk9v 2/ https://t.co/ScMV2BrNMP
14b) However, 4F-PCCs appear to have significantly longer effects on endogenous thrombin potential #ETP compared with andexanet alfa, & peak thrombin generation was also higher with 4F-PCC than with andexanet alfa. See
First #antidote for #apixaban and rivaroxaban approved. #pharmacy #Cardiology #HealthcareForAll https://t.co/k2YeH1Y1wP
12b) In the #ANNEXA-A/R studies in healthy volunteers, no thrombotic events occurred (see
18a) #Andexanet: Ph 3⃣ Studies #ANNEXA_A: pts on #Apixaban 5mg BID x 3.5d #ANNEXA_R: pts on #Rivaroxaban 20mg Daily x 4d Patients: Healthy, older, non-bleeding Primary Efficacy Measure: mean % change in anti-#FXa activity
Factor Xa inhibitors can cause bleeding; andexanet was designed to reverse this anticoagulant effect. Recent research shows it rapidly and effectively restores thrombin generation with minimal adverse events, making it…
This episode discusses how and when to reverse anticoagulation in bleeding emergency patients, focusing on protocols and recent advances like the use of andexanet alfa for reversing factor Xa inhibitors efficiently and…
In the ANNEXA-A and -R studies, andexanet alfa (AA) reduced anti-FXa activity and restored thrombin generation in healthy older volunteers Maximal effect was noted within 2-5 min of bolus and sustained throughout the infusion https://t.co/DzXjwZhk9v 2/ https://t.co/ScMV2BrNMP
18a) #Andexanet: Ph 3⃣ Studies #ANNEXA_A: pts on #Apixaban 5mg BID x 3.5d #ANNEXA_R: pts on #Rivaroxaban 20mg Daily x 4d Patients: Healthy, older, non-bleeding Primary Efficacy Measure: mean % change in anti-#FXa activity
@sanchit_turaga in RCT (low numbers) no safety issues https://t.co/ryAFUelrbA
RT @cardiomet_CE: 14b) However, 4F-PCCs appear to have significantly longer effects on endogenous thrombin potential #ETP compared with and…
RT @cardiomet_CE: 12b) In the #ANNEXA-A/R studies in healthy volunteers, no thrombotic events occurred (see
14b) However, 4F-PCCs appear to have significantly longer effects on endogenous thrombin potential #ETP compared with andexanet alfa, & peak thrombin generation was also higher with 4F-PCC than with andexanet alfa. See
12b) In the #ANNEXA-A/R studies in healthy volunteers, no thrombotic events occurred (see
@PharmDFarmD @FND_pharmacy @LRayRx @MeganARech https://t.co/3LaXLNZUIE Here is the open access NEJM link. To my knowledge, CSL Behring has not completed anything similar although some independent investigators did look at the effects of aPCC as mentioned
@ki5_sanocchi こちら自体は大丈夫…ということでいいですよね？ https://t.co/Sh0uL6M6Wb
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
RT @drdangayach: #chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRX…
#chestchat T2: ICH: Blood pressure control: lower is better INTERACT2, ATACH2 https://t.co/q4eCRXTVuT https://t.co/q4eCRXTVuT Reversal agents for DOACs: ANNEXA https://t.co/Czb2dMISBX Praxbind https://t.co/cAtqnc3FWD
RT @badralshubaily: First #antidote for #apixaban and rivaroxaban approved. #pharmacy #Cardiology #HealthcareForAll https://t.co/k2YeH1…
RT @badralshubaily: First #antidote for #apixaban and rivaroxaban approved. #pharmacy #Cardiology #HealthcareForAll https://t.co/k2YeH1…
First #antidote for #apixaban and rivaroxaban approved. #pharmacy #Cardiology #HealthcareForAll https://t.co/k2YeH1Y1wP
@STL_Biotech 2015 was before Andexxa approval First clinical trial published in NEJM is in 2015 Clearly those guidelines are outdated see https://t.co/mWcKDzpX5b
NF
SM
CM
BA
TM
AM
KM
CH
MA
VF
VF
CM
CC
DM
VM
JP
با
PB